Groton manufacturing commitment
Pfizer will invest $650 million in a 220,000-square-foot manufacturing center in Groton, Conn., according to reporting from Supply Chain 24/7 in its Sourcing & Procurement section. The site is intended to manufacture drugs for clinical trials.
For procurement, finance, and operations leaders tracking pharma supply capacity, a multi-year greenfield project of this scale signals long-lead capital planning and eventual new sourcing and qualification work tied to trial-material production.
Timeline
The center is scheduled to open in mid-2031, which leaves a long runway for construction, equipment procurement, and validation before commercial trial-manufacturing use.
What leaders can watch
Details beyond spend, footprint, location, purpose, and opening timing were not included in the source report. Teams that depend on trial supply chains may want to follow Pfizer disclosures and regional supplier announcements as the project advances.
- $650 million total investment
- 220,000 square feet in Groton
- Clinical trial drug manufacturing focus
- Mid-2031 opening target
